| HOME | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|---|
| ||||||||||||||||||||||||||||||||
1 Department of Internal Medicine and Clinical Gerontology, Centre Hospitalier Universitaire Purpan-Casselardit, Toulouse, France.
2 Department of Epidemiology and Public Health, University of Toulouse, Toulouse, France.
3 INSERM U558, Toulouse, France.
Address correspondence to S. Gillette-Guyonnet, PhD, Service de Médecine Interne et de Gérontologie Clinique, Pavillon J. P. Junod, Centre Hospitalier Universitaire La Grave-Casselardit, 170 avenue de Casselardit, TSA40031, 31059 Toulouse cedex 9, France. E-mail: gillette.s{at}chu-toulouse.fr/sophie.gillette{at}free.fr
Background. Alzheimer's disease is fast becoming a major public health concern with serious economic consequences. The cholinesterase inhibitors (CEIs) offer some benefit in the symptomatic treatment of the disease. This study aims to investigate the effect of CEIs on three clinically relevant domains (rapid cognitive decline, institutionalization, and weight loss) in patients with Alzheimer's disease.
Methods. A prospective observational study was performed in which a population of 455 Alzheimer's disease patients were recruited and followed up for at least 1 year between 1994 and 2002. Patients were reevaluated at 6 monthly intervals using standardized neurocognitive and geriatric evaluations in addition to complete clinical examination, standard paraclinical investigations, and recording of treatment received.
Results. The risk of rapid cognitive deterioration was significantly decreased in patients taking CEIs for at least 1 year compared to untreated patients (odds ratio [OR] = 0.56, 95% confidence interval [CI], 0.34–0.93; p =.025). The potential benefit of CEI use was also found on institutionalization (OR = 0.2, 95% CI, 0.08–0.48; p <.001) and weight loss (OR = 0.56, 95% CI, 0.32–0.97; p =.039) after 1 year of follow-up.
Conclusion. The special interest of this study is that all patients were recruited and followed in the same center with the same management care plan and the same medical team. This follow-up offers us a unique opportunity to compare the 1-year evolution of the disease in clinical practice before and after the marketing of CEIs and allows us to demonstrate a clinically significant improvement in patient outcome over time.
This article has been cited by other articles:
 |
|
 |
|
  S. Gillette-Guyonnet, S. Andrieu, F. Nourhashemi, E. Reynish, and B. Vellas RESPONSE TO LETTER FROM GARCIA AND COLLEAGUES ON CHOLINESTERASE INHIBITORS AND ALZHEIMER'S DISEASE OUTCOMES J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2007; 62(6): 679 - 680. [Full Text] [PDF]
|
|
|
|
|
|
H. Y. Cheng COULD THE POTENTIAL BENEFITS OF CHOLINESTERASE INHIBITORS IN ALZHEIMER'S DISEASE BE REDUCED AFTER ADJUSTING FOR COEXISTING DISEASES AND MULTIPLE MEDICATIONS? J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2007; 62(6): 680 - 680. [Full Text] [PDF]
|
|
|
|
|
|
S. Gillette-Guyonnet, S. Andrieu, F. Nourhashemi, E. Reynish, and B. Vellas RESPONSE TO LETTER FROM CHENG ON CHOLINESTERASE INHIBITORS AND ALZHEIMER'S DISEASE OUTCOMES J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2007; 62(6): 680 - 680. [Full Text] [PDF]
|
|
|
|
|
|
L. Ferrucci A Year of Excellence in Geriatric Research and Some New Dishes on the Menu J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2007; 62(5): 516 - 518. [Full Text] [PDF]
|
|
|
|
|
|
A. Garcia, K. Thompson, K. Zanibbi, S. Geick, and R. Adams CHOLINESTERASE INHIBITORS AND ALZHEIMER'S DISEASE OUTCOMES J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2007; 62(5): 570 - 570. [Full Text] [PDF]
|
|
| HOME | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|---|
